Table S1.
Linkage to scFv does not affect liposomal zeta potential or DXR encapsulation
| Fresh formulation | Size (nm) | PDI | Zeta (ζ) potential | Encapsulation efficiency |
|---|---|---|---|---|
| DXR-L | 86.30±1.34 | 0.057±0.002 | −16.3±0.60 | 98% |
| DXR-L scFv G8 | 94.26±0.66 | 0.058±0.004 | −16±0.70 | 95% |
| DXR-L scFv Hyb3 | 98.30±1.31 | 0.098±0.02 | −16.3±0.49 | 80% |
| At 1 week | ||||
| DXR-L | 86.4 | 0.060 | −15.9 | 97% |
| DXR-L scFv G8 | 102.8±1.51 | 0.073±0.01 | −17.6±0.057 | 94% |
| DXR-L scFv Hyb3 | 99.42±1.05 | 0.083±0.006 | −17.6±1.21 | 77% |
| At 2 weeks | ||||
| DXR-L | 86.25 | 0.65 | – | 95% |
| DXR-L scFv G8 | 104.2±2.46 | 0.094±0.02 | – | 92% |
| DXR-L scFv Hyb3 | 99.28±1.50 | 0.084±0.006 | – | 75% |
| At 4 weeks | ||||
| DXR-L | 86.58±1.42 | 0.076±0.006 | – | 95% |
| DXR-L scFv G8 | 106.7±1.81 | 0.083±0.007 | – | 90% |
| DXR-L scFv Hyb3 | 107.4±1.15 | 0.068±0.002 | – | 74% |
Notes: Three independent batches of three liposome formulations (DXR-L, DXR-L scFv G8, and DXR-L scFv Hyb3) were characterized for size, PDI, surface charge, and encapsulation efficiency for up to 4 weeks (stored in HEPES buffer pH 6.7, at 4°C temperature). Measurements were done in triplicate and are given as average and SD (n=3).
Abbreviations: DXR, doxorubicin; DXR-L, DXR-loaded liposome; PDI, polydispersity index.